Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate

Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in the US in coming years. The company Thursday announced it had inked a deal [?]